

Proposal Subject: Review of CDC *V.p.* Illness Information

Specific NSSP Guide Reference: Section II Model Ordinance Chapter II @.05

Text of Proposal/ Requested Action N/A

Public Health Significance: The number of cases of *V.p.* associated with consumption of shellfish reported to the CDC by states in 2009 shows a significant increase from previous years. There were not any large outbreaks that occurred during the year, but the total number of reported cases was the second highest since 1998, which included cases from outbreaks associated with product from all three coasts. The large number of 2009 cases, in the absence of a large outbreak, suggests that the ISSC needs to review current CDC *V.p.* illness information and determine the adequacy of current control strategies in the NSSP.

The VMC and the ISSC Executive Board briefly discussed the 2009 reported illnesses and agreed that a *V.p.* subcommittee should discuss the CDC reported information and make appropriate recommendations for VMC review. The purpose of this proposal is to notify the interested parties that change to the controls of Chapter II @.05 may be discussed at the ISSC 2011 Biennial Meeting.

Cost Information (if available):

Action by 2011 Task Force II Recommended adoption of Vibrio Management Committee recommendation on Proposal 11-206 to refer to an appropriate committee as determined by the Conference Chairman.

Action by 2011 General Assembly Adopted the recommendation of Task Force II on Proposal 11-206.

Action by FDA February 26, 2012 Concurred with Conference action on Proposal 11-206.

Action by 2013 Vibrio Management Committee The Vibrio Management Committee recommended that FDA request CDC to be present at Task Force II to answer questions on their data including, (1) does the data include exposures to other foods especially to crustaceans, (2) does data include actual cases or under-reporting factors, and (3) explanation of the *V.p.* death data

Action by 2013 Task Force II Recommended referral of Proposal 11-206 back to committee. Task Force II further recommended that CDC be asked to participate as a member of the committee.

Action by 2013 General Assembly Adopted recommendation of Task Force II on Proposal 11-206.

Action by FDA May 5, 2014 Concurred with Conference action on Proposal 11-206.